country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-188021

Copy Link Print Information

CD22 CAR mRNA

cis a chimeric antigen receptor mRNA targeting CD22. When delivered via CD8-targeted LNP, CD22 CAR mRNA inhibits tumor growth in Nalm6 tumor-bearing mouse models. CD22 CAR mRNA can be used for research on hematologic malignancies.

For research use only. We do not sell to patients.

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

CD22 CAR mRNA Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

In Vitro

Nb8-H3-conjugated lipid 15 LNPs encapsulating CD22 CAR mRNA (22-V4) (24 h) induce CD22 CAR expression in 50% of primary human CD8⁺ T cells and mediate robust CAR-specific B cell depletion in vitro^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

CD22 CAR mRNA delivered via CD8-targeted LNPs (0.3 mg/kg; i.v.; 5 doses on days 7, 11, 14, 18, 21) significantly reduces tumor burden in an aggressive humanized hematological malignancy mouse model, with complete elimination of tumor cells from liver and spleen tissues^[1].
CD22 CAR mRNA delivered via CD8-targeted LNPs (0.3 mg/kg; i.v.; single dose) achieves robust, specific CAR expression on human CD8⁺ T cells in vivo and mediates near-complete B cell depletion without significant toxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NSG MHC I/II KO mice (female, 10 weeks old, engrafted with luciferase-expressing Nalm6 cells and human PBMCs)^[1]
Dosage:

0.3 mg/kg
Administration:

i.v.; 5 doses on days 7, 11, 14, 18, 21
Result:

Decreased average radiance to approximately 6 × 10⁶ p/s/cm²/sr on day 26, compared to >2 × 10⁷ p/s/cm²/sr in control groups.
Eliminated all CD22-expressing tumor cells from the spleen and liver.

Chemical Information

SMILES

[CD22 CAR mRNA]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Lemgart VT, et al. Reprogramming CD22 CAR-T cells in vivo using CD8-targeted mRNA-LNPs to treat hematological malignancies. Molecular therapy : the journal of the American Society of Gene Therapy. 2026 May 06;34(5):2621-2636. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote